RA Capital-backed cell therapy player in the neoantigen game grabs a $121M megaround to fund first human studies
There’s more than 1 way to skin a mouse. And anyone who figures out the best way in oncology can open the door to a valuable new platform technology.
Undaunted by the pioneers who have gone ahead in personalized neoantigen R&D work, the team at Achilles Therapeutics operating out of Stevenage in the UK believe they have found a better therapeutic approach — starting with non-small cell lung cancer and in melanoma.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.